
Zynex Inc (ZYXI) Stock Forecast & Price Target
Zynex Inc (ZYXI) Analyst Ratings
Bulls say
Zynex Inc. has experienced a notable 16% year-over-year growth in orders for FY2024, reflecting the company's strong market demand for its electrotherapy and pain management products. Management anticipates significant cost savings of approximately $35 million annually starting in the second half of 2025, alongside plans to increase revenue per sales representative to $1 million, which could enhance overall productivity. Moreover, the company's innovative product offerings, particularly the positively evaluated laser-based system, position Zynex as a leader in non-opioid pain management solutions, further solidifying its competitive advantage in the medical device market.
Bears say
Zynex Inc has indicated a significant decline in sales for Q1 2025, projecting revenues of at least $30 million, which represents a 37% year-over-year drop and a 35% sequential decline, coupled with an expected EPS loss. The company's Q4 2024 revenue was reported at $46 million, which was a 3% year-over-year decrease and below projections, highlighting a concerning trend in both device and supply sales. A notable revision of 2025 revenue expectations to $140 million, down from the previously projected $241 million, underscores the financial difficulties and uncertainties surrounding Zynex's operations and future performance.
This aggregate rating is based on analysts' research of Zynex Inc and is not a guaranteed prediction by Public.com or investment advice.
Zynex Inc (ZYXI) Analyst Forecast & Price Prediction
Start investing in Zynex Inc (ZYXI)
Order type
Buy in
Order amount
Est. shares
0 shares